A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

By Elhilali M.M.   Ramsey E.W.   Barkin J.   Casey R.W.   Boake R.C.   Beland G.   Fradet Y.   Trachtenberg J.   Orovan W.L.   Schick E.   Klotz L.H.  

Urology, Vol. 47, Iss. 3, 1996-03 ,pp. : 335-342

Elsevier

Access to resources Recommend Favorite

Diet and benign prostatic hyperplasia: a study in Greece

By Lagiou P.   Wuu J.   Trichopoulou A.   Hsieh C.-C.   Adami H.-O.   Trichopoulos D.  

Urology, Vol. 54, Iss. 2, 1999-08 ,pp. : 284-290

Elsevier

Access to resources Recommend Favorite

Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled study

By Andersen J.T.   Ekman P.   Wolf H.   Beisland H.O.   Johansson J.E.   Kontturi M.   Lehtonen T.   Tveter K.  

Urology, Vol. 46, Iss. 5, 1995-11 ,pp. : 631-637

Elsevier

Access to resources Recommend Favorite

Nocturia and benign prostatic hyperplasia

By Yoshimura K.   Ohara H.   Ichioka K.   Terada N.   Matsui Y.   Terai A.   Arai Y.  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 786-790

Elsevier

Access to resources Recommend Favorite

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years - how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

By Hudson P.B.   Boake R.   Trachtenberg J.   Romas N.A.   Rosenblatt S.   Narayan P.   Geller J.   Lieber M.M.   Elhilali M.   Norman R.   Patterson L.   Perreault J.-P.   Malek G.H.   Bruskewitz R.C.   Roy J.B.   Ko A.   Jacobsen C.A.   Stoner E.  

Urology, Vol. 53, Iss. 4, 1999-04 ,pp. : 690-695

Elsevier

Access to resources Recommend Favorite